New ESC/EACTS guidelines for the management of aortic valve disease: key takeaways and implications of long-term TAVR results based on recent explant and redo-TAVR registry outcomes
- 1St. Bartholomew’s Hospital, West Smithfield, London, EC1A 7BE UK
Abstract
Background: The 2025 European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines for valvular heart disease represent a pivotal update, emphasizing earlier intervention for aortic stenosis (AS) and broader indications for transcatheter aortic valve replacement (TAVR). These changes are driven by randomized trial data demonstrating TAVR’s safety in lower-risk patients. However, as TAVR expands to younger cohorts, long-term durability remains a concern.
Main body: This narrative review examines key guideline updates for aortic valve disease, focusing on aortic stenosis (AS) and aortic regurgitation (AR), and integrates insights from recent registries (2020–2025) on TAVR explantation and redo-TAVR outcomes. Data from the EXPLANT-TAVR, EXPLANTORREDO-TAVR and FRANCE 2/FRANCE TAVI registries reveal reintervention rates of 0.3–1.7% at 8 years, with redo-TAVR offering superior short-term survival (30-day mortality 1.5–6.2%) compared to explantation (11.9–13.6%). Structural valve deterioration (SVD), leaflet thrombosis, and endocarditis predominate failure causes, underscoring the need for lifetime management strategies.
Conclusion: Implications include refined patient selection, enhanced imaging surveillance, and Heart Team-driven decisions to balance procedural benefits against reintervention risks.
Related
- A Review of Guidelines for the Use of Tranexamic Acid in the Management of Postpartum Hemorrhage and Assessment of Associated Maternal Outcomes.
- Prehospital management and outcomes of traumatic cardiac arrest in older adults: a French nationwide registry study
- Real-World Management and Outcomes of Probable and Indeterminate UIP Patterns on HRCT: A Retrospective Cohort Study and Implications for the 2022 IPF Guideline
- Global perspectives on dietary management of small intestinal bacterial overgrowth (SIBO): a systematic review of clinical guidelines, consensus statements and expert recommendations
- Thrombophilia Testing After VTE and in Related Clinical Contexts: Is It Necessary, and Does It Change Management? Appraisal of Evidence, Guidelines, and Clinical Yield
BibTeX
@article{paul2026esceacts,
title = {{New ESC/EACTS guidelines for the management of aortic valve disease: key takeaways and implications of long-term TAVR results based on recent explant and redo-TAVR registry outcomes}},
author = {Saptarshi Paul},
journal = {Journal of Cardiothoracic Surgery},
year = {2026},
month = aug,
doi = {10.1186/s13019-026-04643-3},
url = {https://doi.org/10.1186/s13019-026-04643-3},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - New ESC/EACTS guidelines for the management of aortic valve disease: key takeaways and implications of long-term TAVR results based on recent explant and redo-TAVR registry outcomes
AU - Saptarshi Paul
PY - 2026
DA - 2026/08/06
JO - Journal of Cardiothoracic Surgery
DO - 10.1186/s13019-026-04643-3
UR - https://doi.org/10.1186/s13019-026-04643-3
AB - Background: The 2025 European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines for valvular heart disease represent a pivotal update, emphasizing earlier intervention for aortic stenosis (AS) and broader indications for transcatheter aortic valve replacement (TAVR). These changes are driven by randomized trial data demonstrating TAVR’s safety in lower-risk patients. However, as TAVR expands to younger cohorts, long-term durability remains a concern. Main body: This narrative review examines key guideline updates for aortic valve disease, focusing on aortic stenosis (AS) and aortic regurgitation (AR), and integrates insights from recent registries (2020–2025) on TAVR explantation and redo-TAVR outcomes. Data from the EXPLANT-TAVR, EXPLANTORREDO-TAVR and FRANCE 2/FRANCE TAVI registries reveal reintervention rates of 0.3–1.7% at 8 years, with redo-TAVR offering superior short-term survival (30-day mortality 1.5–6.2%) compared to explantation (11.9–13.6%). Structural valve deterioration (SVD), leaflet thrombosis, and endocarditis predominate failure causes, underscoring the need for lifetime management strategies. Conclusion: Implications include refined patient selection, enhanced imaging surveillance, and Heart Team-driven decisions to balance procedural benefits against reintervention risks.
SN - 1749-8090
ER -